Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $34 to $33.
Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $34 to $33.